Wells Fargo
HOWL icon

Wells Fargo’s Werewolf Therapeutics HOWL Stock Holding History

Wells Fargo’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-459
Closed -$500 – 7222
2025
Q2 		$500 Sell
459
-17,397
-97% -$17.9K ﹤0.01% 6372
2025
Q1 		$17.4K Buy
17,856
+875
+5% +$1.15K ﹤0.01% 5752
2024
Q4 		$25.1K Buy
16,981
+4,135
+32% +$8.43K ﹤0.01% 5703
2024
Q3 		$27.2K Buy
12,846
+359
+3% +$817 ﹤0.01% 5551
2024
Q2 		$30.5K Buy
12,487
+12,293
+6,337% +$59K ﹤0.01% 5461
2024
Q1 		$1.26K Buy
194
+40
+26% +$233 ﹤0.01% 6102
2023
Q4 		$594 Buy
154
+8
+5% +$20 ﹤0.01% 6345
2023
Q3 		$312 Buy
146
+10
+7% +$28 ﹤0.01% 6467
2023
Q2 		$415 Buy
136
+40
+42% +$113 ﹤0.01% 6529
2023
Q1 		$250 Buy
96
+2
+2% +$6 ﹤0.01% 6713
2022
Q4 		$193 Buy
94
+6
+7% +$16 ﹤0.01% 6629
2022
Q3 		$0 Buy
88
+38
+76% +$206 ﹤0.01% 6934
2022
Q2 		$0 Sell
50
-5,697
-99% -$26K ﹤0.01% 7079
2022
Q1 		$26K Sell
5,747
-6,952
-55% -$48.7K ﹤0.01% 5923
2021
Q4 		$151K Buy
+12,699
New +$192K ﹤0.01% 5425

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo's HOWL Position: Q3 2025 in Review

Wells Fargo sold out of Werewolf Therapeutics (HOWL) in Q3 2025, closing a stake of 459 shares — an estimated $500 sold.

Wells Fargo first reported a position in HOWL in Q4 2021 and held it in 15 quarters. The position peaked at $151K in Q4 2021. 62 funds tracked by Wall St. Rank hold HOWL as of Q3 2025.

  • Wells Fargo reported no remaining Werewolf Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Wells Fargo sold 459 Werewolf Therapeutics shares in Q3 2025, an estimated $500.
  • Wells Fargo first reported a position in Werewolf Therapeutics in Q4 2021 and held it in 15 quarters.
  • Wells Fargo's Werewolf Therapeutics position peaked at $151K in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2025.

Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.